Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CAMPTOSAR

« Back to Dashboard
Camptosar is a drug marketed by Pfizer Inc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in CAMPTOSAR is irinotecan hydrochloride. There are thirty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.

Summary for Tradename: CAMPTOSAR

Patents:2
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: CAMPTOSAR

Clinical Trials for: CAMPTOSAR

Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Status: Completed Condition: Sarcoma

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Status: Terminated Condition: Astrocytoma; Glioma; Oligodendroglioma

Panitumumab and Irinotecan for Malignant Gliomas
Status: Terminated Condition: Malignant Glioma of Brain

Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
Status: Not yet recruiting Condition: Childhood Solid Tumors

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
Status: Recruiting Condition: Colorectal Cancer

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
Status: Terminated Condition: Malignant Gliomas

A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
Status: Withdrawn Condition: Central Nervous System Metastases; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Recruiting Condition: Small Cell Lung Carcinoma; Non Small Cell Lung Carcinoma; Irinotecan Sensitive Cancers

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
Status: Completed Condition: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
Status: Completed Condition: Unspecified Adult Solid Tumor, Protocol Specific

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-001Jun 14, 1996RXYes6,794,370*PED<disabled>Y<disabled>
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-003Aug 5, 2010RXYes<disabled><disabled>
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-001Jun 14, 1996RXYes6,403,569*PED<disabled>Y<disabled>
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-002Jun 14, 1996RXYes6,403,569*PED<disabled>Y<disabled>
Pfizer Inc
CAMPTOSAR
irinotecan hydrochloride
INJECTABLE;INJECTION020571-002Jun 14, 1996RXYes6,794,370*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CAMPTOSAR

Drugname Dosage Strength RLD Submissiondate
irinotecan hydrochlorideInjection20 mg/mL, 2 mL and 5 mL vialsCamptosar7/26/2004
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc